ADC Therapeutics S.A. (NYSE: ADCT) Stock Competitors & Peer Comparison

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, VRTX has a market cap of 121.5B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while VRTX trades at $480.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas VRTX's P/E ratio is 25.44. In terms of profitability, ADCT's ROE is +0.65%, compared to VRTX's ROE of +0.21%. Regarding short-term risk, ADCT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check VRTX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, REGN has a market cap of 78.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while REGN trades at $773.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas REGN's P/E ratio is 16.67. In terms of profitability, ADCT's ROE is +0.65%, compared to REGN's ROE of +0.18%. Regarding short-term risk, ADCT is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check REGN's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ADCT's ROE is +0.65%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ADCT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check VRNA's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ARGX has a market cap of 52.5B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ARGX trades at $864.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ARGX's P/E ratio is 76.22. In terms of profitability, ADCT's ROE is +0.65%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, ADCT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ARGX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ADCT's ROE is +0.65%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ADCT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check SGEN's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, RVMDW has a market cap of 41.8B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while RVMDW trades at $10.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas RVMDW's P/E ratio is -2.42. In terms of profitability, ADCT's ROE is +0.65%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ADCT is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check RVMDW's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, RVMD has a market cap of 41.1B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while RVMD trades at $194.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas RVMD's P/E ratio is -27.36. In terms of profitability, ADCT's ROE is +0.65%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ADCT is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check RVMD's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ONC has a market cap of 34.5B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ONC trades at $330.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ONC's P/E ratio is 72.26. In terms of profitability, ADCT's ROE is +0.65%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ADCT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ONC's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ALNY has a market cap of 29.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ALNY trades at $226.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ALNY's P/E ratio is 39.46. In terms of profitability, ADCT's ROE is +0.65%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ADCT is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ALNY's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ROIV trades at $34.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ROIV's P/E ratio is -35.55. In terms of profitability, ADCT's ROE is +0.65%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ADCT is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ROIV's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while INCY trades at $120.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas INCY's P/E ratio is 16.21. In terms of profitability, ADCT's ROE is +0.65%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ADCT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check INCY's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, BNTX has a market cap of 23.1B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while BNTX trades at $91.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas BNTX's P/E ratio is -19.77. In terms of profitability, ADCT's ROE is +0.65%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ADCT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check BNTX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, MRNA has a market cap of 22.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while MRNA trades at $57.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas MRNA's P/E ratio is -6.99. In terms of profitability, ADCT's ROE is +0.65%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ADCT is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check MRNA's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while UTHR trades at $523.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas UTHR's P/E ratio is 19.15. In terms of profitability, ADCT's ROE is +0.65%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ADCT is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for ADCT.Check UTHR's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while INSM trades at $99.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas INSM's P/E ratio is -17.17. In terms of profitability, ADCT's ROE is +0.65%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ADCT is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check INSM's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ADCT's ROE is +0.65%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ADCT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check BGNE's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ADCT's ROE is +0.65%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ADCT is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ADCT.Check DNA-WT's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, GMAB has a market cap of 17.8B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while GMAB trades at $29.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas GMAB's P/E ratio is 20.88. In terms of profitability, ADCT's ROE is +0.65%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ADCT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check GMAB's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, NBIX has a market cap of 16.7B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while NBIX trades at $164.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas NBIX's P/E ratio is 24.00. In terms of profitability, ADCT's ROE is +0.65%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ADCT is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check NBIX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, JAZZ has a market cap of 16.4B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while JAZZ trades at $259.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas JAZZ's P/E ratio is 20.34. In terms of profitability, ADCT's ROE is +0.65%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ADCT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check JAZZ's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, BBIO has a market cap of 16.1B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while BBIO trades at $81.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas BBIO's P/E ratio is -21.94. In terms of profitability, ADCT's ROE is +0.65%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ADCT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check BBIO's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ASND has a market cap of 15.2B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ASND trades at $244.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ASND's P/E ratio is -101.07. In terms of profitability, ADCT's ROE is +0.65%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ADCT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ASND's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while EXEL trades at $56.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas EXEL's P/E ratio is 16.77. In terms of profitability, ADCT's ROE is +0.65%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ADCT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check EXEL's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ARWR has a market cap of 12.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ARWR trades at $89.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ARWR's P/E ratio is -41.67. In terms of profitability, ADCT's ROE is +0.65%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ADCT is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ARWR's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ADCT's ROE is +0.65%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ADCT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check KRTX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, BMRN has a market cap of 11.7B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while BMRN trades at $60.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas BMRN's P/E ratio is 29.19. In terms of profitability, ADCT's ROE is +0.65%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ADCT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check BMRN's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, MDGL has a market cap of 11.7B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while MDGL trades at $506.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas MDGL's P/E ratio is -39.65. In terms of profitability, ADCT's ROE is +0.65%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ADCT is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check MDGL's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while TECH trades at $72.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas TECH's P/E ratio is 37.16. In terms of profitability, ADCT's ROE is +0.65%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ADCT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check TECH's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ADCT's ROE is +0.65%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ADCT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check RNAM's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, SMMT has a market cap of 11B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while SMMT trades at $13.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas SMMT's P/E ratio is -8.60. In terms of profitability, ADCT's ROE is +0.65%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ADCT is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check SMMT's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, AXSM has a market cap of 10.9B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while AXSM trades at $210.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas AXSM's P/E ratio is -55.40. In terms of profitability, ADCT's ROE is +0.65%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ADCT is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check AXSM's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, HALO has a market cap of 9.9B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while HALO trades at $83.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas HALO's P/E ratio is 18.02. In terms of profitability, ADCT's ROE is +0.65%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ADCT is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check HALO's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, CYTK has a market cap of 9.8B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while CYTK trades at $78.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas CYTK's P/E ratio is -13.48. In terms of profitability, ADCT's ROE is +0.65%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ADCT is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check CYTK's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, KRYS has a market cap of 9.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while KRYS trades at $321.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas KRYS's P/E ratio is 43.42. In terms of profitability, ADCT's ROE is +0.65%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ADCT is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check KRYS's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ADCT's ROE is +0.65%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ADCT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check RXDX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ABVX trades at $125.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ABVX's P/E ratio is -65.62. In terms of profitability, ADCT's ROE is +0.65%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ADCT is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ABVX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, IONS has a market cap of 9.2B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while IONS trades at $54.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas IONS's P/E ratio is -32.02. In terms of profitability, ADCT's ROE is +0.65%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ADCT is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check IONS's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ADCT's ROE is +0.65%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ADCT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check NUVL's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, SYRE has a market cap of 9.1B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while SYRE trades at $101.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas SYRE's P/E ratio is -50.45. In terms of profitability, ADCT's ROE is +0.65%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ADCT is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ADCT.Check SYRE's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while CRNX trades at $83.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas CRNX's P/E ratio is -16.35. In terms of profitability, ADCT's ROE is +0.65%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ADCT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check CRNX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while PTGX trades at $136.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas PTGX's P/E ratio is -75.03. In terms of profitability, ADCT's ROE is +0.65%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ADCT is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check PTGX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ADCT's ROE is +0.65%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ADCT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check IMGN's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while PRAX trades at $311.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas PRAX's P/E ratio is -23.19. In terms of profitability, ADCT's ROE is +0.65%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ADCT is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check PRAX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, KYMR has a market cap of 8.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while KYMR trades at $105.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas KYMR's P/E ratio is -29.57. In terms of profitability, ADCT's ROE is +0.65%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ADCT is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check KYMR's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ADCT's ROE is +0.65%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ADCT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check BPMC's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ALKS has a market cap of 8.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ALKS trades at $50.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ALKS's P/E ratio is 52.28. In terms of profitability, ADCT's ROE is +0.65%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ADCT is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ALKS's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while APGE trades at $134.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas APGE's P/E ratio is -30.99. In terms of profitability, ADCT's ROE is +0.65%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ADCT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check APGE's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas CERE's P/E ratio is -16.47. In terms of profitability, ADCT's ROE is +0.65%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ADCT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check CERE's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while IMVT trades at $38.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas IMVT's P/E ratio is -14.74. In terms of profitability, ADCT's ROE is +0.65%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ADCT is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check IMVT's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while PCVX trades at $55.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas PCVX's P/E ratio is -7.95. In terms of profitability, ADCT's ROE is +0.65%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ADCT is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check PCVX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, TGTX has a market cap of 7.5B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while TGTX trades at $49.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas TGTX's P/E ratio is 16.75. In terms of profitability, ADCT's ROE is +0.65%, compared to TGTX's ROE of +0.84%. Regarding short-term risk, ADCT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check TGTX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ADCT's ROE is +0.65%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ADCT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check MTSR's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, COGT has a market cap of 7.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while COGT trades at $42.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas COGT's P/E ratio is -20.30. In terms of profitability, ADCT's ROE is +0.65%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ADCT is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check COGT's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while IBRX trades at $7.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas IBRX's P/E ratio is -8.18. In terms of profitability, ADCT's ROE is +0.65%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ADCT is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ADCT.Check IBRX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while RYTM trades at $108.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas RYTM's P/E ratio is -33.80. In terms of profitability, ADCT's ROE is +0.65%, compared to RYTM's ROE of -2.01%. Regarding short-term risk, ADCT is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check RYTM's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ADCT's ROE is +0.65%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ADCT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check MRUS's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ADCT's ROE is +0.65%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ADCT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ACLX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas RETA's P/E ratio is -66.29. In terms of profitability, ADCT's ROE is +0.65%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ADCT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check RETA's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ERAS has a market cap of 6.4B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ERAS trades at $18.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ERAS's P/E ratio is -19.76. In terms of profitability, ADCT's ROE is +0.65%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ADCT is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ERAS's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, MIRM has a market cap of 6.4B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while MIRM trades at $104.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas MIRM's P/E ratio is -7.67. In terms of profitability, ADCT's ROE is +0.65%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ADCT is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check MIRM's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while BLTE trades at $156.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas BLTE's P/E ratio is -84.10. In terms of profitability, ADCT's ROE is +0.65%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ADCT is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check BLTE's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while CGON trades at $72.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas CGON's P/E ratio is -30.64. In terms of profitability, ADCT's ROE is +0.65%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ADCT is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check CGON's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ADCT's ROE is +0.65%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ADCT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check CNTA's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, XENE has a market cap of 6.2B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while XENE trades at $64.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas XENE's P/E ratio is -13.62. In terms of profitability, ADCT's ROE is +0.65%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ADCT is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check XENE's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, LGND has a market cap of 6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while LGND trades at $301.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas LGND's P/E ratio is 36.07. In terms of profitability, ADCT's ROE is +0.65%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ADCT is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check LGND's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while PTCT trades at $69.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas PTCT's P/E ratio is -29.66. In terms of profitability, ADCT's ROE is +0.65%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ADCT is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check PTCT's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while SRRK trades at $47.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas SRRK's P/E ratio is -13.31. In terms of profitability, ADCT's ROE is +0.65%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ADCT is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check SRRK's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ADCT's ROE is +0.65%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ADCT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check CDTX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ADCT's ROE is +0.65%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ADCT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ABCM's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ADCT's ROE is +0.65%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ADCT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ISEE's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas APLS's P/E ratio is 38.35. In terms of profitability, ADCT's ROE is +0.65%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ADCT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check APLS's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while TVTX trades at $63.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas TVTX's P/E ratio is -254.64. In terms of profitability, ADCT's ROE is +0.65%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ADCT is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ADCT.Check TVTX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while CRSP trades at $52.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas CRSP's P/E ratio is -10.39. In terms of profitability, ADCT's ROE is +0.65%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ADCT is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check CRSP's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, DYN has a market cap of 4.8B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while DYN trades at $26.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas DYN's P/E ratio is -8.07. In terms of profitability, ADCT's ROE is +0.65%, compared to DYN's ROE of -0.64%. Regarding short-term risk, ADCT is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check DYN's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while EWTX trades at $44.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas EWTX's P/E ratio is -26.93. In terms of profitability, ADCT's ROE is +0.65%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ADCT is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check EWTX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas TERN's P/E ratio is -51.41. In terms of profitability, ADCT's ROE is +0.65%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ADCT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check TERN's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ACAD has a market cap of 4.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ACAD trades at $28.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ACAD's P/E ratio is 13.31. In terms of profitability, ADCT's ROE is +0.65%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ADCT is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ACAD's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, DFTX has a market cap of 4.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while DFTX trades at $42.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas DFTX's P/E ratio is N/A. In terms of profitability, ADCT's ROE is +0.65%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ADCT is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check DFTX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, DNTH has a market cap of 4.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while DNTH trades at $109.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas DNTH's P/E ratio is -26.73. In terms of profitability, ADCT's ROE is +0.65%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ADCT is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check DNTH's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, CAI has a market cap of 4.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while CAI trades at $16.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas CAI's P/E ratio is -88.56. In terms of profitability, ADCT's ROE is +0.65%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ADCT is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check CAI's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ADCT's ROE is +0.65%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ADCT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check FOLD's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while CELC trades at $92.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas CELC's P/E ratio is -23.72. In terms of profitability, ADCT's ROE is +0.65%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ADCT is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check CELC's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ADCT's ROE is +0.65%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ADCT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check AKRO's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while MANE trades at $111.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas MANE's P/E ratio is -34.17. In terms of profitability, ADCT's ROE is +0.65%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ADCT is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check MANE's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ADCT's ROE is +0.65%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ADCT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ALPN's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ELVN has a market cap of 4.4B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ELVN trades at $57.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ELVN's P/E ratio is -36.59. In terms of profitability, ADCT's ROE is +0.65%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ADCT is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for ADCT.Check ELVN's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas OPT's P/E ratio is -1.52. In terms of profitability, ADCT's ROE is +0.65%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ADCT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check OPT's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ADCT's ROE is +0.65%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ADCT is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check PRTC's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ADCT's ROE is +0.65%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ADCT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check MRTX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ADPT trades at $24.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ADPT's P/E ratio is -45.46. In terms of profitability, ADCT's ROE is +0.65%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ADCT is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ADPT's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ADCT's ROE is +0.65%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ADCT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check CPRX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while VKTX trades at $33.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas VKTX's P/E ratio is -7.96. In terms of profitability, ADCT's ROE is +0.65%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, ADCT is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check VKTX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, DNLI has a market cap of 3.8B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while DNLI trades at $24.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas DNLI's P/E ratio is -8.39. In terms of profitability, ADCT's ROE is +0.65%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ADCT is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check DNLI's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ADCT's ROE is +0.65%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ADCT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check RYZB's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ADCT's ROE is +0.65%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ADCT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check CBAY's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, ORKA has a market cap of 3.7B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while ORKA trades at $96.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas ORKA's P/E ratio is -50.58. In terms of profitability, ADCT's ROE is +0.65%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, ADCT is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check ORKA's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while TNGX trades at $28.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas TNGX's P/E ratio is -35.37. In terms of profitability, ADCT's ROE is +0.65%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, ADCT is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ADCT.Check TNGX's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, RCUS has a market cap of 3.6B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while RCUS trades at $28.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas RCUS's P/E ratio is -8.85. In terms of profitability, ADCT's ROE is +0.65%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, ADCT is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check RCUS's competition here

ADC Therapeutics S.A. (NYSE: ADCT) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADCT stands at 139.9M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ADCT is priced at $1.12 on the NYSE, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADCT currently has a P/E ratio of -1.05, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ADCT's ROE is +0.65%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ADCT is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ADCT.Check SWTX's competition here